9 articles for N Hashimoto
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.
Banyu Tsukuba Research Institute
Discovery of Novel Bicyclic Pyrazoles as Potent PIP5K1C Inhibitors.
Kyorin Pharmaceutical Co., Ltd.
Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment.
Kyorin Pharmaceutical Co. Ltd.
Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
Mitsubishi Tanabe Pharma Corporation
Discovery of a potent, orally available furopyridine derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
Mitsubishi Tanabe Pharma Corporation
Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.
Kyorin Pharmaceutical
Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors.
Merck Research Laboratories